Showing results (101-110 of 122) with videos related to

Sort By:
Pageof 13
Leukemia|March 9, 2018
Early myeloma-related death in elderly patients: development of a clinical prognostic score and evaluation of response sustainability rolePaula Rodríguez-Otero, María Victoria Mateos, Joaquín Martínez-López, et al.
Hemasphere|October 15, 2025
European Myeloma Network Group Consensus Statement on the use of next-generation sequencing for prognostic stratification of newly diagnosed multiple myelomaNiccolò Bolli, Mattia D'Agostino, Tina Bagratuni, et al.
Blood|February 7, 2015
The cellular origin and malignant transformation of Waldenström macroglobulinemiaBruno Paiva, Luis A Corchete, Maria-Belen Vidriales, et al.
Blood|April 28, 2016
Minimal residual disease monitoring and immune profiling in multiple myeloma in elderly patientsBruno Paiva, Maria-Teresa Cedena, Noemi Puig, et al.
Hemasphere|June 22, 2026
Minimally invasive characterization of peripheral blood measurable residual disease in multiple myeloma using high-sensitivity detection of ctDNA by next-generation sequencingNatalia Buenache, Marta Lasa, Andrés Arroyo, et al.
Leukemia|March 25, 2022
LocoMMotion: a prospective, non-interventional, multinational study of real-life current standards of care in patients with relapsed and/or refractory multiple myelomaMaria-Victoria Mateos, Katja Weisel, Valerio De Stefano, et al.
Advances in Therapy|November 28, 2025
Comparative Efficacy of Talquetamab vs. Real-World Physician's Choice of Treatment in Triple-Class-Exposed Relapsed/Refractory Multiple Myeloma: Updated Analyses of MonumenTAL-1 vs. LocoMMotion/MoMMentHermann Einsele, Philippe Moreau, Nizar Bahlis, et al.
Blood|May 22, 2025
Ultrasensitive detection of circulating multiple myeloma cells by next-generation flow after immunomagnetic enrichmentMarta Lasa, Carmen Gonzalez, Laura Notarfranchi, et al.
The Lancet. Haematology|August 6, 2025
Induction therapy with bortezomib, melphalan, and prednisone followed by lenalidomide and dexamethasone versus carfilzomib, lenalidomide, and dexamethasone with or without daratumumab in older, fit patients with newly diagnosed multiple myeloma (GEM-2017FIT): a phase 3, open-label, multicentre, randomised clinical trialMaría-Victoria Mateos, Bruno Paiva, M Teresa Cedena, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 22, 2024
Curative Strategy for High-Risk Smoldering Myeloma: Carfilzomib, Lenalidomide, and Dexamethasone (KRd) Followed by Transplant, KRd Consolidation, and Rd MaintenanceMaría-Victoria Mateos, Joaquin Martínez-López, Paula Rodriguez Otero, et al.
Pageof 13